Cancer Immunotherapy Today and Tomorrow
575 Memorial Drive, Cambridge, MA
9:00AM - 3:00PM
Immune-based cancer therapies are producing durable responses and significant overall survival times for more tumor types. In the past year, the FDA significantly expanded the immunotherapy armamentarium when it approved CAR T-cells for treating adults with certain B-cell lymphomas. This CME event will deliver scientific discussion and clinical strategies of interest to researchers, oncologists, primary care physicians and specialists.
Keynote Speakers (Partial List)
John F. DiPersio, MD, PhD
Washington University School of Medicine in St. Louis
Mario Sznol, MD
Yale Cancer Center
David Avigan, MD, and David McDermott, MD, Directors, and Jacalyn Rosenblatt, MD, Deputy Director Immunotherapy Institute, Cancer Center at Beth Israel Deaconess Medical Center
The course will provide concise summaries of today’s immunotherapies and those that are on the way. Registrants will receive the curriculum on a flash drive on the day of the event.
- Therapeutic role and management of CAR T-cell therapy
- Breakthroughs on the horizon: What will be next?
- Review of immunotherapy science
- Personalized cancer vaccines for hematologic malignancies
- Checkpoint blockade therapies for solid tumors: melanoma and breast, kidney, lung and pancreatic tumors
- Impact of combination therapies
- Managing toxicity and other immune-related adverse events
- Current clinical trials
Credits for Physicians, Advanced Practice Providers and Nurses
The Harvard Medical School is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The Harvard Medical School designates this live activity for a maximum of 5.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.